Inferra AIResearch Tools

Inferra AI / Company / AZN

AstraZeneca

AZN · Health Care

Last earnings Oct 30, 2026

Key results

Total revenuequarter

7%

Total Revenue up 7%, with double-digit growth in Oncology, R&I and Rare Disease offsetting headwinds from Farxiga and Brilinta loss of exclusivity and volume-based procurement in China &#xA0

SEC original ↗AstraZeneca — Earnings release (6-K report)6-KOct 30, 2026

AI analysis

Q3 2026 · reported Oct 30, 2026

Based on: Earnings release — transcript not held

Headline figures

MetricQ3 2026Prior qtrYear ago
Total revenue7%6%—

6-K · Oct 30, 2026

Guidance · company-stated

Tax rate

“is expected to be between 18-22%”

Guidance stated in the release for FY 2026; figures as stated.

Next earningsNo verified date on fileNo date is estimated or imported
General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

AstraZeneca Q3 2026 — Total Revenue up 7%, with double-digit growth in Oncology, R&I and Rare Disease offsetting headwinds from Farxiga and Brilinta loss of exclusivity and volume-based procurement in China &#xA0

Based on: Earnings release — transcript not held

Guidance & outlook

Tax rate: “Tax rate is expected to be between 18-22%”

Tax rate (“FY 2026”)
“The Core Tax rate is expected to be between 18-22%  ”

Guidance stated in the release for FY 2026; figures as stated.

Strategy & priorities

  Kendall Square R&D Centre   In October, AstraZeneca formally opened its new global strategic R&D centre, in Kendall Square, Cambridge, Massachusetts.

SEC original ↗AstraZeneca — Earnings release (6-K report)6-KOct 30, 2026

  insitro In October, AstraZeneca entered into a strategic drug discovery collaboration and licensing agreement with insitro.

SEC original ↗AstraZeneca — Earnings release (6-K report)6-KOct 30, 2026

Priority Review US VOLGA September 2026  * Perioperative treatment with Imfinzi in combination with neoadjuvant enfortumab vedotin for patients with MIBC who are ineligible for or have declined cisplatin-based chemotherapy.

SEC original ↗AstraZeneca — Earnings release (6-K report)6-KOct 30, 2026

Priority Review US OBERON / TITANIA / PROSPERO August 2026   * Add-on maintenance treatment for adult patients with COPD.

SEC original ↗AstraZeneca — Earnings release (6-K report)6-KOct 30, 2026

Priority Review US HICKORY/MULBERRY/CHESTNUT September 2026   Patients with hypophosphatasia aged ≥2 years.

SEC original ↗AstraZeneca — Earnings release (6-K report)6-KOct 30, 2026

Risks & headwinds

    AstraZeneca received the My Green Lab and International Institute for Sustainable Laboratories (I2SL) 2026 Freezer Challenge Award for the Biotech and Pharmaceutical sector for the third time.

SEC original ↗AstraZeneca — Earnings release (6-K report)6-KOct 30, 2026

The Freezer Challenge is a global initiative that promotes more sustainable laboratory operations through improved freezer and cold storage management, helping reduce energy use and improve efficiency.

SEC original ↗AstraZeneca — Earnings release (6-K report)6-KOct 30, 2026

What changed vs prior quarter

Total revenue — prior quarter passage and this quarter's passage are both cited.

SEC original ↗AstraZeneca — Earnings release (6-K report)6-KOct 30, 2026

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care
Documents

Filings

60 documents

Earnings releases

1 document

Presentations

0 documents

No presentations for AstraZeneca are held in this edition of the library.

Transcripts

0 documents

No transcripts for AstraZeneca are held in this edition of the library.

Mentioned by

5 companies

Other tracked companies whose held documents mention AstraZeneca by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.